KYTX Earnings Date: Nov 11, 2026 (Estimated) — Kyverna Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology
Updated
When is KYTX's next earnings date?
Kyverna Therapeutics, Inc. (KYTX) is expected to report Q3 2026 earnings on Wednesday, November 11, 2026 at 4:00 PM ET (after market close); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.68.
How did KYTX do in its last earnings report?
In its most recent report on Aug 12, 2026, Kyverna Therapeutics, Inc. posted EPS of -$0.63 versus the -$0.68 estimate, a beat of 7.1%. The stock's 1-day post-earnings move was +0.7%.
How much does KYTX stock move after earnings?
KYTX beat EPS estimates in 7 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 7.0% (up or down) in the day after earnings.
About Kyverna Therapeutics, Inc.
Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and lupus nephritis, as well as multiple sclerosis and systemic sclerosis. The company is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole blood rapid manufacturing; and KYV-201, an allogeneic CD19 CAR T-cell product candidate. It has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-12 | -0.68 | -0.63 | +7.12% | — | ✅ Beat | +0.75% | +5.99% | -8.35% | |
| 2026-08-11 | Q2 2026 | -0.68 | -0.63 | +7.35% | $0 | ✅ Beat | +0.37% | +5.99% | -8.35% |
| 2026-05-12 | Q1 2026 | -0.73 | -0.66 | +9.59% | $0 | ✅ Beat | +5.38% | -14.96% | -23.07% |
| 2026-03-26 | Q4 2025 | -0.84 | -0.80 | +4.76% | $0 | ✅ Beat | -2.86% | +10.46% | +11.96% |
| 2025-11-12 | Q3 2025 | -0.96 | -0.85 | +11.46% | $0 | ✅ Beat | -11.60% | +12.28% | +19.78% |
| 2025-08-12 | Q2 2025 | -1.03 | -0.97 | +5.83% | $0 | ✅ Beat | +14.90% | +9.27% | +37.58% |
| 2025-03-27 | Q4 2024 | -0.79 | -0.74 | +6.33% | $0 | ✅ Beat | -15.07% | -16.35% | -12.95% |
| 2024-11-13 | Q3 2024 | -0.80 | -0.80 | +0.00% | $0 | ➖ Inline | -5.14% | -18.58% | -12.65% |
Showing last 8 quarters.